Biological Activity:

DMXAA (Vadimezan) is a potent and selective mSTING agonist, selective for mouse STING over human STING. It induces IFN-β and cytokine production from bone marrow-derived dendritic cells. It can cause tumor regression following intratumoral administration in mouse tumor models. DMXAA induces an adaptive immune response to reduce systemic tumor growth and provides immunological memory against autologous tumor re-challenge.


How to Use:

In vitro: DMXAA was used at 10-20 µM final concentration in various assays.
In vivo: Single dose DMXAA by intratumoral (IT) administration at 500 µg to get antitumor efficacy.

Reference:

• 1. Phillips RM, et al. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. (1999) Biochem Pharmacol. 58(2):303-10.
• 2. Shirey KA, et al. The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. (2011) J Leukoc Biol. 89(3):351-7. 
• 3. Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. (2015) Cell Rep. 11(7):1018-30.